Abstract
Not all patients presenting with acute coronary syndrome (ACS) are able to receive reperfusion therapy. These include patients who present late (after 12 h) or who have bleeding diathesis. Studies have found a number of factors affect the decision to reperfuse. Other treatment options are needed for those patients with acute ST‐elevation myocardial infarction (STEMI). Low‐molecular weight heparin, such as enoxaparin, now offers these patients the opportunity for successful intervention. Several clinical trials have determined its superiority over unfractionated heparin as an adjunct during thrombolytic therapy. Currently, a trial is underway to determine the effect of enoxaparin in combination with tirofiban in patients with STEMI ineligible for reperfusion therapy. Blinded data for the entire patient cohort shows excellent efficacy and safety in these patients.
Keywords: acute coronary syndrome, enoxaparin, low‐molecular‐weight heparin, myocardial infarction, reperfusion, thrombolytic therapy, unfractionated heparin
Full Text
The Full Text of this article is available as a PDF (38.4 KB).
References
- 1. Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez‐Sendon J, GRACE Investigators: Practice variation and missed opportunities for reperfusion in ST‐segment elevation myocardial infarction: Findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002; 359 (9304): 373–377 [DOI] [PubMed] [Google Scholar]
- 2. Brodi BR, Stuckey TD, Wall TC, Kissling G, Hansen CJ, Muncy DB, Weintraub RA, Kelly TA: Importance of time to reperfusion for 30‐day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 1998; 32: 1312–1319 [DOI] [PubMed] [Google Scholar]
- 3. Barron HV, Bowlby LJ, Breen T, Rogers WJ, Canto JG, Zhang Y, Tiefenbrunn AJ, Weaver WD: Use of reperfusion therapy for acute myocardial infarction in the United States: Data from the National Registry of Myocardial Infarction 2. Circulation 1998; 97 (2): 1150–1160 [DOI] [PubMed] [Google Scholar]
- 4. Cragg Dr, Friedman HZ, Bonema JD, Jaiyesimi IA, Ramos RG, Timmis GC, O'Neill WW, Schreiber TL: Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy. Ann Intern Med 1991; 115 (3): 173–177 [DOI] [PubMed] [Google Scholar]
- 5. Doorey AJ, Michelson EL, Topol EJ: Thrombolytic therapy of acute myocardial infarction. Keeping the unfulfilled promises. J Am Med Assoc 1992; 268 (21): 3108–3114 [PubMed] [Google Scholar]
- 6. GISSI Avoidable Delay Study Group : Epidemiology of avoidable delay in the care of patients with acute myocardial infarction in Italy. A GISSI‐generated study. Arch Intern Med 1995; 155 (14): 1481–1488 [PubMed] [Google Scholar]
- 7. Ellerbeck EF, Jencks SF, Radford MJ, Kresowik TF, Craig AS, Gold JA, Krumholz HM, Vogel RA: Quality of care for Medicare patients with acute myocardial infarction. A four‐state pilot study from the Cooperative Cardiovascular Project. J Am Med Assoc 1995; 273 (19): 1509–1514 [PubMed] [Google Scholar]
- 8. Gurwitz JH, McLaughlin TJ, Willison DJ, Guadagnoli E, Hauptman PJ, Gao X, Soumerai SB: Delayed hospital presentation in patients who have had acute myocardial infarction. Ann Intern Med 1997; 126 (8): 593–599 [DOI] [PubMed] [Google Scholar]
- 9. Dauerman HL, Pinto DS, Ho KK, Gibson CM, Kuntz RE, Cohen DJ, Baim DS, Carrozza JP Jr: Outcome of patients with acute myocardial infarction who are ineligible for primary angioplasty trials. Cath Cardiovasc Interven 2000; 49 (3): 237–243 [DOI] [PubMed] [Google Scholar]
- 10. Cohen M, Antman EM, Gurfinkel E, Turpie AG, Furst J, Bigonzi F, Radley D: Impact of enoxaparin low‐molecular‐weight heparin in patients with Q‐wave myocardial infarction. Am J Cardiol 2000; 86 (5): 553–556 [DOI] [PubMed] [Google Scholar]
- 11. Ross AM, Molhoek P, Lundergan C, Knudtson M, Draoui Y, Regalado L, Le Louer V, Bigonzi F, Schwartz W, de Jong E, Coyne K, HART II Investigators: Randomized comparison of enoxaparin, a low‐molecular‐weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: Second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001; 104 (6): 648–652 [DOI] [PubMed] [Google Scholar]
- 12. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT‐3) Investigators : Efficacy and safety of tenecteplace in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT‐3 randomized trial in acute myocardial infarction. Lancet 2001; 358 (9282): 605–613 [DOI] [PubMed] [Google Scholar]
- 13. Zhao XQ, Théroux P, Snapinn SM, Sax FL: Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non‐Q‐wave myocardial infarction. Angiographic results from the PRISM‐PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM‐PLUS Investigators. Circulation 1999; 100 (15): 1609–1615 [DOI] [PubMed] [Google Scholar]
- 14. Cohen M, Théroux P, Weber S, Laramee P, Huynh T, Borzak S, Diodati JG, Squire IB, Deckelbaum LI, Thornton AR, Harris KE, Sax FL, Lo MW, White HD: Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol 1999; 71 (3): 273–281 [DOI] [PubMed] [Google Scholar]
- 15. Cohen M, Théroux P, Borzak S, Frery MJ, White HD, Van Mieghem W, Senatore F, Liss J, Mukherjee R, Harris K, Bigonzi F, on behalf of the ACUTE II Investigators : Randomized double blind safety study of enoxaparin versus unfractionated heparin in tirofiban and aspirin treated patients with non‐ST segment elevation. Acute Coronary Syndromes: The ACUTE II Study. Am Heart J 2002; (October) (in press) [DOI] [PubMed]
- 16. Topol EJ, The GUSTO V Investigators: Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomized trial. Lancet 2001; 357 (9272): 1905–1914 [DOI] [PubMed] [Google Scholar]